Skip to Main Content
Table 6.

Breast cancer odds ratios (95% confidence intervals) by ER and PR status and CYP1A2*F genotype

n*AAACCCP
ER negative 205/1,370 1.0 0.8 (0.6-1.1) 0.7 (0.4-1.2) 0.08 
ER positive 703/1,370 1.0 0.9 (0.8-1.1) 0.8 (0.6-1.2) 0.26 
PR negative 269/1,370 1.0 0.9 (0.7-1.1) 0.6 (0.4-1.1) 0.08 
PR positive 605/1,370 1.0 0.9 (0.7-1.1) 0.9 (0.6-1.3) 0.41 
ER/PR negative 165/1,370 1.0 0.8 (0.5-1.1) 0.5 (0.3-1.1) 0.03 
ER/PR positive 562/1,370 1.0 0.9 (0.8-1.2) 0.9 (0.6-1.3) 0.41 
n*AAACCCP
ER negative 205/1,370 1.0 0.8 (0.6-1.1) 0.7 (0.4-1.2) 0.08 
ER positive 703/1,370 1.0 0.9 (0.8-1.1) 0.8 (0.6-1.2) 0.26 
PR negative 269/1,370 1.0 0.9 (0.7-1.1) 0.6 (0.4-1.1) 0.08 
PR positive 605/1,370 1.0 0.9 (0.7-1.1) 0.9 (0.6-1.3) 0.41 
ER/PR negative 165/1,370 1.0 0.8 (0.5-1.1) 0.5 (0.3-1.1) 0.03 
ER/PR positive 562/1,370 1.0 0.9 (0.8-1.2) 0.9 (0.6-1.3) 0.41 

NOTE: Adjusted by logistic regression for age at blood draw, race/ethnicity, age at menarche, parity and age at first birth.

*

No. cases/no. controls; 431 cases had missing ER status and 465 cases had missing PR status.

P value for gene dosage term assigned 1, 2, and 3 for 0, 1, and 2 variant alleles, respectively. The P value for comparison of gene dosage effects between the ER/PR-negative and ER/PR-positive groups by polytomous logistic regression was not statistically significant (P = 0.13).

Close Modal

or Create an Account

Close Modal
Close Modal